Experts will explore not only the potential impact of machine learning on healthcare systems and drug development, but also provide insights on what investors and partners should consider before engaging in financing or co-development with AI healthcare companies.
Preceding the panel, Alex Zhavoronkov, CEO of Insilico Medicine, will provide an introduction, announcing the official launch of AAIH, which will include the organization’s inaugural board meeting on Wednesday, January 9, in San Francisco.
WHO: Panelists are Alex Lash, National Biotech Editor, Xconomy; Brandon Allgood, CTO and Co-founder of Numerate; John Baldoni, Senior VP of In-Silico Drug Discovery, GSK; Maria Luisa Pineda, CEO and Co-Founder, Envisagenics; Bill Martin, President and COO, BlackThorn Therapeutics; Angeli Moeller, Co-Lead of AI, Head of Research IT Business Partnering, Bayer; and Ben Newton, CDO, GE Healthcare Life Sciences.
WHAT: The Future of AI-Powered Healthcare session and reception.
WHEN: Monday, January 7, 4 pm
WHERE: Parc 55 San Francisco, 55 Cyril Magnin Street; 4th Floor, Cyril Magnin Ballroom